Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer von Konecny, Gottfried E

Volltext

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes von VON MINCKWITZ, Gunter, UNTCH, Michael, JACKISCH, Christian, KAUFMANN, Manfred, KONECNY, Gottfried E, DENKERT, Carsten, NEKLJUDOVA, Valentina, MEHTA, Keyur, LOIBL, Sibylle, BLOHMER, Jens- Uwe, COSTA, Serban D, EIDTMANN, Holger, FASCHING, Peter A, GERBER, Bernd, EIERMANN, Wolfgang, HILFRICH, Jörn, HUOBER, Jens

Volltext

Current and future role of neoadjuvant therapy for breast cancer von Untch, Michael, Konecny, Gottfried E, Paepke, Stefan, von Minckwitz, Gunter

Volltext

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer von KONECNY, Gottfried E, CHEN WANG, GOSTOUT, Bobbie, PODRATZ, Karl C, KEENEY, Gary, WANG, He-Jing, HARTMANN, Lynn C, SLAMON, Dennis J, GOODE, Ellen L, HAMIDI, Habib, WINTERHOFF, Boris, KALLI, Kimberly R, DERING, Judy, GINTHER, Charles, CHEN, Hsiao-Wang, DOWDY, Sean, CLIBY, William

Volltext

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma von Lin, Kevin K, Harrell, Maria I, Oza, Amit M, Oaknin, Ana, Ray-Coquard, Isabelle, Tinker, Anna V, Helman, Elena, Radke, Marc R, Say, Carmen, Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D, Maloney, Lara, O'Malley, David M, Chambers, Setsuko K, Kaufmann, Scott H, Scott, Clare L, Konecny, Gottfried E, Coleman, Robert L, Sun, James X, Giordano, Heidi, Brenton, James D, Harding, Thomas C, McNeish, Iain A, Swisher, Elizabeth M

Volltext

Cyclin-dependent kinase pathways as targets for women's cancer treatment von Konecny, Gottfried E

Volltext

Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification von Konecny, Gottfried E, Winterhoff, Boris, Wang, Chen

Volltext

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: R... von UNTCH, Michael, FASCHING, Peter A, STICKELER, Elmar, HARBECK, Nadia, HÖSS, Cornelia, KAHLERT, Steffen, BECK, Thomas, FETT, Werner, MEHTA, Keyur M, VON MINCKWITZ, Gunter, LOIBL, Sibylle, KONECNY, Gottfried E, HASMÜLLER, Stephan, LEBEAU, Annette, KREIENBERG, Rolf, CAMARA, Oumar, MÜLLER, Volkmar, DU BOIS, Andreas, KÜHN, Thorsten

Volltext

Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer von Konecny, Gottfried E

Volltext

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial von Swisher, Elizabeth M, Dr Prof, Lin, Kevin K, PhD, Oza, Amit M, Prof, Scott, Clare L, PhD, Giordano, Heidi, MA, Sun, James, PhD, Konecny, Gottfried E, MD, Coleman, Robert L, Prof, Tinker, Anna V, MD, O'Malley, David M, MD, Kristeleit, Rebecca S, MD, Ma, Ling, MD, Bell-McGuinn, Katherine M, MD, Brenton, James D, Prof, Cragun, Janiel M, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, Prof, Harrell, Maria I, PhD, Mann, Elaina, MS, Kaufmann, Scott H, Prof, Floquet, Anne, MD, Leary, Alexandra, MD, Harding, Thomas C, PhD, Goble, Sandra, MS, Maloney, Lara, BA, Isaacson, Jeff, PhD, Allen, Andrew R, MD, Rolfe, Lindsey, MBChB, Yelensky, Roman, PhD, Raponi, Mitch, PhD, McNeish, Iain A, Prof

Volltext

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis o... von Oza, Amit M., Tinker, Anna V., Oaknin, Ana, Shapira-Frommer, Ronnie, McNeish, Iain A., Swisher, Elizabeth M., Ray-Coquard, Isabelle, Bell-McGuinn, Katherine, Coleman, Robert L., O'Malley, David M., Leary, Alexandra, Chen, Lee-may, Provencher, Diane, Ma, Ling, Brenton, James D., Konecny, Gottfried E., Castro, Cesar M., Giordano, Heidi, Maloney, Lara, Goble, Sandra, Lin, Kevin K., Sun, James, Raponi, Mitch, Rolfe, Lindsey, Kristeleit, Rebecca S.

Volltext

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) von Swisher, Elizabeth M., Kwan, Tanya T., Oza, Amit M., Tinker, Anna V., Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L., Aghajanian, Carol, Konecny, Gottfried E., O’Malley, David M., Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-may, Wahner Hendrickson, Andrea E., Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S., Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H., Elvin, Julia A., Lin, Douglas I., Chambers, Setsuko K., Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L., Lin, Kevin K., McNeish, Iain A.

Volltext

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage,... von Konecny, Gottfried E, Dr, Finkler, Neil, Prof, Garcia, Agustin A, MD, Lorusso, Domenica, MD, Lee, Paula S, MD, Rocconi, Rodney P, MD, Fong, Peter C, MBBS, Squires, Matt, PhD, Mishra, Kaushal, PhD, Upalawanna, Allison, PharmD, Wang, Yongyu, MD, Kristeleit, Rebecca, MD

Volltext

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer von Konecny, Gottfried E.

Volltext

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab von Hardesty, Melissa M., Krivak, Thomas C., Wright, Gail S., Hamilton, Erika, Fleming, Evelyn L., Belotte, Jimmy, Keeton, Erika K., Wang, Ping, Gupta, Divya, Clements, Aine, Gray, Heidi J., Konecny, Gottfried E., Moore, Richard G., Richardson, Debra L.

Volltext

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer von KONECNY, Gottfried E, WINTERHOFF, Boris, KALLI, Kimberly R, FINN, Richard S, GINTHER, Charles, JONES, Siân, VELCULESCU, Victor E, RIEHLE, Darren, CLIBY, William A, RANDOLPH, Sophia, KOEHLER, Maria, HARTMANN, Lynn C, KOLAROVA, Teodora, SLAMON, Dennis J, JINGWEI QI, MANIVONG, Kanthinh, DERING, Judy, GUORONG YANG, CHALUKYA, Meenal, WANG, He-Jing, ANDERSON, Lee

Volltext

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells von KONECNY, Gottfried E, PEGRAM, Mark D, KEITH, Barry R, GILMER, Tona M, BERGER, Mark, PODRATZ, Karl C, SLAMON, Dennis J, VENKATESAN, Natarajan, FINN, Richard, GUORONG YANG, RAHMEH, Martina, UNTCH, Michael, RUSNAK, David W, SPEHAR, Glenn, MULLIN, Robert J

Volltext

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines von Papp, Eniko, Hallberg, Dorothy, Konecny, Gottfried E., Bruhm, Daniel C., Adleff, Vilmos, Noë, Michaël, Kagiampakis, Ioannis, Palsgrove, Doreen, Conklin, Dylan, Kinose, Yasuto, White, James R., Press, Michael F., Drapkin, Ronny, Easwaran, Hariharan, Baylin, Stephen B., Slamon, Dennis, Velculescu, Victor E., Scharpf, Robert B.

Volltext

Targeting Fibroblast Growth Factor Pathways in Endometrial Cancer von Winterhoff, Boris, Konecny, Gottfried E

Volltext

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study von Moore, Kathleen N, Chambers, Setsuko K, Hamilton, Erika P, Chen, Lee-May, Oza, Amit M, Ghamande, Sharad A, Konecny, Gottfried E, Plaxe, Steven C, Spitz, Daniel L, Geenen, Jill J J, Troso-Sandoval, Tiffany A, Cragun, Janiel M, Rodrigo Imedio, Esteban, Kumar, Sanjeev, Mugundu, Ganesh M, Lai, Zhongwu, Chmielecki, Juliann, Jones, Suzanne F, Spigel, David R, Cadoo, Karen A

Volltext